SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cytokinetics, Inc. (CYTK)

CYTK RSS Feed
Add CYTK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 9/19/2017 2:01:01 PM - Followers: 66 - Board type: Free - Posts Today: 0


 

 

Cytokinetics is a different kind of company. It is increasingly unusual that an emerging growth biotechnology company would be dedicated to the discovery, development and commercialization of therapeutics. Similarly, it is more and more uncommon for a biopharmaceutical company to leverage their expertise in one area, in our case the cytoskeleton  and the biology of muscle function, to tackle the pursuit of new treatments for multiple disease areas. However, the most important distinguishing feature of Cytokinetics is instead found in our commitment to innovation that has translated our focus on the cytoskeleton into a Research and Development pipeline of multiple, first-in-class compounds. All of the programs we are pursuing offer entirely novel therapeutic approaches to severe unmet clinical needs. The reason is simple. Innovative therapeutics are much more likely to bring substantial benefits to patients. That is our goal.

Based in South San Francisco, we employ approximately 81 employees. Working collaboratively in a company that embodies uncommon values, Cytokinetics' devoted and passionate personnel, are all focused on advancing novel therapeutics to dramatically improve the lives of patients. With purpose and passion, we have committed to make an important impact on serious medical illnesses. We are pleased that you are visiting our website to learn more about Cytokinetics.

Company Links:

Investor's Relations

SEC Filings

Cytokenetics Team

Pipeline

Omecamtiv Mecarbil Clinical Trial (PH 2) (October 2013)


CK-2017357 Clinical Trial (PH 2) (September 2012) 




Third Party Links:

NASDAQ 

Market Watch

Barchart









 




 >

 

 .

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
CYTK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CYTK News: Current Report Filing (8-k) 09/19/2017 05:01:44 PM
CYTK News: Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patie... 09/19/2017 07:30:00 AM
CYTK News: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting 09/18/2017 07:30:00 AM
CYTK News: Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting 09/11/2017 04:00:00 PM
CYTK News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 04:49:36 PM
News News Alert: Current Report Filing (8-k) 09/19/2017 05:01:44 PM
PostSubject
#1439   $10M milestone reached :) H2R 09/19/17 02:01:01 PM
#1438   New presentation at the 21st Annual Heart Failure H2R 09/11/17 06:24:49 PM
#1437   ..And up again, no news, well, except the H2R 08/28/17 06:58:18 PM
#1436   New SoS Analysis: Bullish.Financial Standing. H2R 08/07/17 03:49:08 PM
#1435   And back down to $13+. What a strange H2R 08/04/17 05:17:11 PM
#1434   ... and now down over 7%! I'm not H2R 08/03/17 11:14:59 AM
#1433   Expected VITALITY-ALS Phase 3: Q4 2017 tracking! H2R 08/02/17 09:17:07 PM
#1432   The financials look good! H2R 08/02/17 09:15:36 PM
#1431   ... followed by a solid day, up %4.95 H2R 08/02/17 09:00:28 PM
#1430   POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF H2R 08/02/17 08:33:01 AM
#1429   New Corporate Pres at http://ir.cytokinetics.com/phoenix.zhtml?c=142156&p=irol-irhome H2R 05/23/17 03:22:57 PM
#1428   Orphan Designation for CYTK Treatment of spinal muscular atrophy H2R 05/12/17 12:08:03 PM
#1427   Thinking a bit more about the offering, CYTK H2R 05/09/17 06:25:51 PM
#1426   CYTK Prices 5.36M Offering at $14.25/Sh H2R 05/09/17 02:24:11 PM
#1425   SoS article after Edaravone FDA approval H2R 05/08/17 01:33:30 PM
#1424   The competition: edaravone approved (Mitsubishi Tanabe Pharma Corp. - H2R 05/05/17 05:52:21 PM
#1423   Cytokinetics and the ALS Association Renew Partnership to H2R 05/04/17 12:51:53 PM
#1422   VITALITY-ALS patients continue on Open Label Extension H2R 04/28/17 11:28:43 AM
#1421   Calendar Update: On Track for ALS Q4 2017 H2R 04/27/17 04:10:03 PM
#1420   From $13.45 to $16.90 in 5 days! H2R 04/26/17 09:55:40 PM
#1419   And the SA author's reply to a comment H2R 04/26/17 09:52:44 PM
#1418   from $12.60 to over $15 in 5 days! H2R 04/24/17 10:41:12 AM
#1417   Positive SA Article: ALS Q42017 + Long Term H2R 04/22/17 07:04:25 PM
#1416   CYTOKINETICS ADDED TO S&P SMALLCAP 600 H2R 04/22/17 07:00:50 PM
#1415   New SOS article on CYTK: H2R 04/06/17 10:28:54 PM
#1414   Impressive Roth Presentation H2R 03/15/17 11:02:47 PM
#1413   New SOS Article on CYTK H2R 03/15/17 05:02:31 PM
#1412   Form 4's are flying around today... H2R 03/02/17 08:38:25 PM
#1411   Expect results from VITALITY-ALS in Q4 2017. H2R 02/16/17 05:14:10 PM
#1410   Estimated Completion Date: Jan 2021 for GALACTIC-HF / NCT02929329 H2R 02/05/17 10:46:16 PM
#1409   Estimated Completion Date: Jul. 2017 for VITALITY-ALS / NCT02496767 H2R 02/05/17 10:36:06 PM
#1408   The Analysts on the call (see Audio Webcast) H2R 02/04/17 02:04:31 PM
#1407   Some context for the recent PR H2R 02/04/17 01:10:13 PM
#1406   CYTOKINETICS AND ROYALTY PHARMA ANNOUNCE $100 MILLION TRANSACTION H2R 02/04/17 12:52:40 PM
#1405   Thanks...figured something was wrong. If the biotech indices north40000 12/02/16 01:09:25 AM
#1404   Wrong article. Below is the one I was H2R 12/02/16 01:04:07 AM
#1403   Lancet date August 2011...what am I missing? north40000 12/01/16 10:29:35 PM
#1402   The Lancet publishes CYTK Ph II Results! H2R 12/01/16 04:33:43 PM
#1401   SoS: sales potential of $10 to $15 billion. H2R 12/01/16 04:29:28 PM
#1400   Amgen will make a $26.7 million milestone payment H2R 12/01/16 04:27:19 PM
#1399   CYTOKINETICS ANNOUNCES START OF GALACTIC-HF, A PHASE 3 H2R 12/01/16 04:25:51 PM
#1398   And Servier would be the European partner for commercialization H2R 09/01/16 09:04:40 AM
#1397   Amgen >> Solid partnership! crudeoil24 09/01/16 08:59:18 AM
#1396   CYTOKINETICS AND AMGEN TO ADVANCE OMECAMTIV MECARBIL TO H2R 09/01/16 08:54:43 AM
#1395   VITALITY-ALS: ENROLLMENT COMPLETE (PHASE 3) H2R 08/19/16 07:18:49 PM
#1394   CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT GLOBAL COLLABORATION H2R 07/27/16 10:47:43 AM
#1393   PHASE 2 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN H2R 04/04/16 10:51:55 AM
#1392   CYTK 11 Short working PAC 12/14/15 11:47:00 AM
#1391   CYTK 11.43 short setup as bear wedge. Trendline PAC 12/11/15 11:42:59 PM
#1390   $CYTK recent news/filings stocktrademan 11/12/15 12:36:48 PM
PostSubject